...for a targeted therapy.With Zegalogue approval, Zealand preparing first U.S. launchFDA approved Zegalogue dasiglucagon from Zealand Pharma A/S...
...suspension, arikace, slit amikacin) 177Lu-PSMA-617, Lu177-PSMA-617 (PSMA-617, AAA617, [18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte...

...be available at that time. Zealand re-obtains amylin analog from Boehringer Boehringer has returned to Zealand Pharma A/S...
...ABT-199 (Compound #), GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) AbbVie Inc. Boehringer Ingelheim GmbH Zealand Pharma A/S Amylin...

...Zealand expands peptide platform with Encycle acquisition Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide...
...U.S. Federal Trade Commission to complete their reviews of the deal. Hongjiang Li, Staff Writer Entresto, sacubitril/valsartan (LCZ696) Zealand Pharma A/S Encycle...

...see “Alexion Deal Lends Late-Stage Support to Stealth” ). Alexion partnered with Affibody AB and Zealand Pharma A/S...

...Review that could Shorten Soliris’ Exclusivity” ). The company’s recent deals include a partnership with Zealand Pharma A/S...

...Parker as CEO, succeeding founding CEO Geoffroy de Ribains. Parker was EVP and CSO at Zealand Pharma A/S...
...CFO at Modus Therapeutics AB (Stockholm, Sweden) since April and previously served as CFO at Zealand Pharma...

...Ahead of NDA submission, Zealand raising cash Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million...
...P2X ligand-gated ion channel 3 Paul Bonanos and Jonathan Block, Associate Editors Dasiglucagon (ZP4207) Aerie Pharmaceuticals Inc. Bellus Health Inc. Zealand Pharma A/S YSOPIA...

...The growth factor modulation company has begun a search for a successor. Peptide therapy company Zealand Pharma A/S...

...Lilly and Co. (NYSE:LLY) and has served as adviser to Verastem's commercial organization since May. Zealand Pharma A/S...
...day-to-day operations and clinical development, respectively, effective immediately. Jonathan Block, Associate Editor Arvinas Inc. Novaremed AG Protalix BioTherapeutics Inc. Verastem Inc. Zealand Pharma A/S Turning...

...the heparin analog. All endpoints met in Zealand's third Phase III trial for hypoglycemia candidate Zealand Pharma A/S...
...Lieu, Staff Writer Dasiglucagon (ZP4207) relugolix (TAK-385) seltorexant (JNJ-42847922, MIN-202) sevuparin (Sevuparin/DF02) SGT-001 Karolinska Development AB Minerva Neurosciences Inc. Modus Therapeutics AB Solid Biosciences Inc. Zealand Pharma A/S Myovant...